Shares of Alder BioPharmaceuticals took a hit Tuesday morning after the biotech reported that Bristol-Myers Squibb had dumped its $1 billion-plus collaboration deal on the IL-6 drug clazakizumab, which had cleared a Phase IIb study for rheumatoid arthritis.

…read more

Source: Bristol-Myers dumps $1B-plus Alder deal, punts rheumatoid arthritis drug


0 No comments